Pages
- 404
- Site Map
- הודעות / חדשות
- וולפורו
- מחקרים ופרסומים
- מידע מקצועי
- עדכונים
- פרטי החברה
- צור קשר עם נציג המוצר
- צור קשר עם נציג המוצר-אייפריים
Posts by category
- Category: עדכונים
- Category: Article
- Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data (08/20/2017)
- Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide (08/01/2017)
- Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients (07/21/2016)
- Phosphate binders in chronic kidney disease: a systematic review of recent data (01/22/2016)
- Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study (09/01/2015)
- Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients (06/01/2015)
- Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide (10/21/2014)
- A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients (09/21/2014)
- The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro (04/21/2014)
- PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease (07/11/2010)
- Category: הודעות וחדשות
- מכתב לרופא (01/28/2017)
- Category: מחקרים ופרסומים
- Category: Article